Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Coleman, Robert L

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. [electronic resource] - The Lancet. Oncology 06 2017 - 779-791 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

1474-5488

10.1016/S1470-2045(17)30279-6 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Bevacizumab--administration & dosage
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial
Cytoreduction Surgical Procedures
Disease-Free Survival
Fallopian Tube Neoplasms--therapy
Female
Humans
Middle Aged
Neoplasm Recurrence, Local--therapy
Neoplasms, Glandular and Epithelial--therapy
Ovarian Neoplasms--therapy
Paclitaxel--administration & dosage
Peritoneal Neoplasms--therapy
Survival Rate
Young Adult